Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2019, Vol. 46 Issue (3): 403-407    DOI: 10.12891/ceog4713.2019
Original Research Previous articles | Next articles
Safety of amniocentesis in normal pregnancies and pregnancies considered high-risk due to fetal genetic anomalies - an observational study
W. Homola1, *(), M. Zimmer1
1Second Department of Gynecology and Obstetrics, Wroclaw Medical University, Wrocław, Poland
Download:  PDF(232KB)  ( 236 ) Full text   ( 6 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Purpose: To evaluate the effect of clinical and demographic factors on the further course of pregnancy and post-procedure complications in healthy and high-risk pregnancies. Materials and Methods: Data of 230 amniocenteses with normal (n=174) and abnormal genetic findings (n=56) were collected retrospectively. Details of birth, neonatal condition, patient characteristics, and post-procedure complications were analysed. Results: The mean maternal age at amniocentesis was 34.50 ± 5 years-old. One hundred (43.48%) were followed by at least one complication. Fetal death occurred after 11 (4.78%) procedures including seven with genetic disorders. There was no significant difference in complication rates between study groups, except for fetal death, which was significantly more common in high-risk pregnancies (p = 0.0017). Abdominal pain correlated with pyrexia and vaginal bleeding. Conclusion: The most severe complications were associated with fetal genetic disorders. The authors conclude that amniocentesis is a safe procedure; however, significant correlations between the incidence of certain complications may be relevant in planning antenatal care.

Key words:  Amniocentesis      Adverse effects      Congenital abnormalities      Prenatal care      Prenatal diagnosis     
Published:  10 June 2019     
*Corresponding Author(s):  W. HOMOLA     E-mail:  wojtek.homola@gmail.com

Cite this article: 

W. Homola, M. Zimmer. Safety of amniocentesis in normal pregnancies and pregnancies considered high-risk due to fetal genetic anomalies - an observational study. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(3): 403-407.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog4713.2019     OR     https://ceog.imrpress.com/EN/Y2019/V46/I3/403

[1] Thanakorn Heetchuay, Thotsapon Trakulmungkichkarn, Noel Pabalan, Nutthaphon Imsom-Somboon. Reference values of fetal atrioventricular time intervals derive from antegrade late diastolic arterial blood flow (ALDAF) from 14 to 40 weeks of gestation[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 867-874.
[2] Gideon Koren, Yusuf C Kaplan. Obesity, neural tube defects and folic acid—A complex relationship[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(2): 223-227.
[3] Saša Raičević, Duško Kljakić, Filip Vukmirović, Miloš Z. Milosavljević. A giant placental chorioangioma with a resultant live birth; a discussion of management options[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(2): 426-430.
[4] Suchaya Luewan, Pakorn Chaksuwat, Tip Pongsuvareeyakul, Theera Tongsong. Prenatal sonographic findings and management of placental mesenchymal dysplasia[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(2): 439-443.
[5] Sureyya Saridas Demir, Erkan Cağliyan, Sabahattin Altunyurt. Retrospective analysis of pregnancy terminations and indications in a tertiary center[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 85-90.
[6] Y.J. Wu, C.J. Yu, W.H. Tian, Z. Xu. Prenatal diagnosis and molecular cytogenetic characterization of two hereditary chromosomal duplications with favorable outcomes[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 789-791.
[7] B.F. Zhou, C.X. Duan, D.L. Tang. Methylmalonic acidemia in prenatal diagnosis[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 617-619.
[8] D. Lu, D. Cao, Q. Zhao, X. Chen. Prenatal diagnosis and genetic counseling of mosaicism for chromosome t (7; 14) with a favorable outcome[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(3): 427-428.
[9] W. B. Wang, Q. Wu, Y. Zhou, X. Zhong, Y. Ge, J. Zhang. A 10-year retrospective study on prenatal cytogenetic analyses[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 248-252.
[10] Q.C. Wu, W.B. Wang, L. Sun, Y.S. Xu, X.J. Xie, X.M. Ma, Z.Y. Su. Mutation analysis of the fibroblast growth factor receptor 3 gene in fetuses with thanatophoric dysplasia, type I[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(1): 7-11.
[11] G. Szabó, J. Rigó Jr.. Prenatal ultrasound diagnosis of abdominal pregnancy of ovarian origin[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(6): 977-979.
[12] K. Miura, A. Higashijima, Y. Hasegawa, S. Miura, KI. Yoshiura, H. Masuzaki. Decreased cell-free but not exosomal miR-518b in maternal plasma is caused by amniocentesis[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(6): 875-879.
[13] D.Y. Ma, G. Liu, C.Y. Luo, A. Liu, J.J. Zhang, P. Hu, J. Cheng, Y.G. Wang, T. Jiang, J.F. Xu. A novel mutation in the mutations in the methyl-CpG-binding protein 2 (MECP2) gene in a Chinese patient with typical Rett syndrome and subsequent prenatal diagnosis[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(6): 924-929.
[14] S. G. Erzincan, N. C. Sayin, C. Inan, M. A. Yuce, F. G. Varol, S. Basaran. Cell-free DNA testing: is it reliable? A case report[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(6): 939-941.
[15] K. Chmaj-Wierzchowska, T. Olejniczak, J. Tuzel, J. Niepsuj-Biniaś, I. Kaczorowska, S. Husam, J. Budna, A. Dera-Szymanowska, K. Olejniczak, K. Szymanowski. Analysis of the cytokine profile (IL-2, IL-4, IL-6, IL-10, IL-17, IFN - γ and TNF-α) on threatened miscarriage[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 661-664.
No Suggested Reading articles found!